Brexit Round Up Pharma (4th Nov. 2016)
This report will collate all key activity from the last week in Westminster, Whitehall, the European Commission, European Parliament and leading stakeholders as it relates to the pharmaceutical and life science sector and Brexit.
Brussels has been relatively quiet during its bank holiday week with no meetings of the Parliament or Council. In the UK, the key development this week has been the High Court ruling that the Prime Minister Theresa May is not entitled to begin the process of leaving the European Union without first consulting the Houses of Parliament.
May has said the referendum - and existing ministerial powers - mean members of Parliament do not need to vote, but campaigners called this unconstitutional. Reaction to the ruling was muted in Brussels with the spokesperson of Commission President Juncker noting only that it is not for the Commission to comment on the internal workings of a member state.
- UK: High Court delivers verdict on Article 50
- UK: Ex-health minister calls for closer relationship with the US, EU and Japan
- UK: Nissan’s Brexit deal
- UK: Pharma asks for assurances following Nissan deal
- UK: UK: MPs quiz International Trade secretary
- EU: CETA signed after several years
- EU: German Council of Economic Experts suggest negotiating for UK to remain in the Single Market
This first edition is free. Dods' will be producing this for a minimum of two years as premium content. If you are interested in accessing future editions, please fill in your details below and our team will get in touch.